Non-Hodgkin Lymphoma News
- Beat AML: Precision Medicine Superior to SOC
- CAR T for All R/R DLBCL Patients: The Jury Is Still Out
- Upped Risk of Death From Other Causes After Hodgkin Lymphoma
- First-in-Class Oral EZH2 Inhibitor Effective in Two Cancers
- Diagnosing Hodgkin Lymphoma in Kids Requires Biopsy, Immunohistochemistry: Guidelines
- Double-Targeted CAR-T Cell Immunotherapy Promising for Refractory Non-Hodgkin Lymphoma
- Cancer Researchers Cross Over to COVID-19 Clinical Trials
- HIV Glasgow 2020 Once-Weekly Investigational MK-8507 Potent Even at Low Doses
- 7 Things to Know About New Lymphoma Drug Tafasitamab
- HFSA 2020 Cell Therapy for Anthracycline Cardiomyopathy Safe, Feasible
- Lawmakers Focus on Price of One Drug, While Others Rise Too
- Mantle Cell Lymphoma: Identifying Patients With Indolent Disease
- Which Drug Therapy for CLL, Time-Limited or Continuous?
- Hematologic Cancers Tied to More Severe COVID-19 Illness
- Azacitidine + Venetoclax Combo Benefits Older Patients With AML
- Cancer Patients With COVID-19 Don't Appear to Be at Higher Risk for Blood Clots
- AACR 2020 Higher Death Rate in Cancer Patients With Nosocomial COVID-19
- Bayer Loses California Appeal of Roundup Verdict, but Damages Are Reduced
- In Remission for 10 Years: Long-term Toxicity Data on CAR T Cells
- Bayer Bets on Science in Bid to Prevent Future Roundup Lawsuits: Legal Experts